Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
Additional Data from MAPLE-HCM Shows AficamtenĀ Improves Cardiac Structure and Function Compared to…
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint…